Phase I trial of CC 359
Phase of Trial: Phase I
Latest Information Update: 18 Feb 2014
At a glance
- Drugs CC 359 (Primary)
- Indications Reperfusion injury
- Focus Adverse reactions
- Sponsors Celgene Corporation
- 18 Feb 2014 Status changed from planning to discontinued.
- 20 Jul 2007 New trial record.